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Objective: It may be difficult for clinicians to estimate the prognosis of pediatric acute transverse myelitis (ATM). The aim of this
study was to define prognostic factors for relapsing disease and poor outcome in pediatric ATM.
Methods: This prospective cohort study included 49 children, 18 boys and 31 girls (median age 13.1 years, IQR 6.5–16.2) with a
first episode of ATM. Factors associated with relapsing disease and poor outcome (Expanded Disability Status Scale (EDSS)  4)
were assessed during a median follow-up of 37 months (IQR 18–75).
Results: In total, 14 patients (29%) experienced  1 relapse(s) and nine patients (18%) had a poor outcome. Factors at onset
associated with relapsing disease included higher age (16.1 vs. 11.6 years, p = 0.002), longer time to maximum severity of symptoms
(5.5 vs. 3 days, p = 0.01), lower maximum EDSS score (4.0 vs. 6.5, p = 0.003), short lesion on spinal MRI (64 vs. 21%, p = 0.006),
abnormalities on brain MRI (93 vs. 44%, p = 0.002) and presence of oligoclonal bands in cerebrospinal fluid (67 vs. 14%, p = 0.004).
The only factor associated with poor outcome was presence of a spinal cord lesion on MRI without cervical involvement (56 vs.
14%, p = 0.02).
Conclusion: Pediatric ATM patients presenting with clinical, radiological and laboratory features associated with multiple scle-
rosis (MS) are at risk for relapsing disease. In absence of these known MS risk factors at onset of disease these patients are at low
risk for relapses. Only a minority of pediatric ATM patients in this cohort have a poor outcome.
 2020 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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Acute transverse myelitis (ATM) is an inflammatory
syndrome of the spinal cord, affecting both children
and adults. In children the estimated incidence is 1.7–
2/million children/year [1–3]. ATM can occur as an iso-
lated syndrome, known as idiopathic ATM. However,
ATM can also be associated with other (multifocal
and/or multiphasic) acquired demyelinating syndromes
(ADS) of the central nervous system, including acute
disseminated encephalomyelitis (ADEM), multiple scle-
rosis (MS) and neuromyelitis optica spectrum disorders
(NMOSD).
The Transverse Myelitis Consortium Working Group
(TMCWG) proposed diagnostic criteria for idiopathic
ATM in 2002 [4]. Children with ATM fulfilling these cri-
teria may subsequently be diagnosed with MS or
NMOSD.
The risk of permanent disability with impairment in
mobility and bladder function may influence the quality
of life of children following ATM [5,6]. It can be chal-
lenging for clinicians to determine the course of the dis-
ease and the rate of recovery during the acute phase,
while these are often the most important concerns of
children with ATM and their families.
The aim of this prospective cohort study was to
define factors predictive for relapsing disease and poor
outcome in children with a first presentation of ATM,
and to compare these to prognostic factors found with
a systematic literature search.
2. Material and methods
2.1. Study participants
All included patients are participants of the Dutch
nationwide multicenter prospective PROUD-kids study
(Predicting the Outcome of a Demyelinating event in
childhood). Patients younger than 18 years with a first
episode of transverse myelitis between June 2006 and
May 2018 were reviewed. They were included if they
had a minimum follow-up of one year and fulfilled the
clinical TMCWG criteria for idiopathic ATM [4]. These
include (1) sensory, motor or autonomic dysfunction
attributable to the spinal cord; (2) bilateral signs and/
or symptoms, not necessarily symmetric; and (3) pro-
gression to nadir (maximum severity of symptoms)
between 4 hours and 21 days following the onset of
symptoms. A clearly defined sensory level was not taken
into account due to the difficulty of a reliable assessment
in young children. Furthermore, the inflammation
TMCWG criteria, i.e. inflammation within the spinal
cord demonstrated by cerebrospinal fluid (CSF) pleocy-
tosis or elevated immunoglobulin G (IgG) index or
gadolinium enhancement on MRI, were not applied,
because a lumbar puncture and gadolinium administra-Please cite this article in press as: Helfferich J et al. Prognostic factors for r
(2021), https://doi.org/10.1016/j.braindev.2020.12.019tion for spinal MRI are not always carried out in pedi-
atric patients. Patients with transverse myelitis due to a
systemic inflammatory disease or present infection were
excluded, including patients with acute flaccid myelitis
associated with enterovirus D68. Moreover, patients
with ADEM were excluded, because of the established
differences in clinical characteristics and outcome
between ATM associated with ADEM and ATM not
associated with ADEM [7]. Patients that fulfilled
Wingerchuk criteria for NMOSD or International Pedi-
atric Multiple Sclerosis Study Group (IPMSSG) criteria
for MS were not excluded, consistent with the aim of
our study and in line with the TMCWG criteria to not
exclude a disease-associated ATM [4,8,9].
2.2. Study parameters and definitions
In the PROUD-kids study, patients are assessed at
baseline and reassessed prospectively, at least annually.
Collected demographic, clinical, laboratory and radio-
logical data at baseline and during follow-up were used
for the current study. These data included date of birth,
medical history, presenting symptoms, prodromal symp-
toms (reported infection or vaccination in the preceding
four weeks), time to nadir (maximum severity of clinical
symptoms), duration of hospitalization, treatment at
onset, recovery measured by using the Expanded Dis-
ability Status Scale (EDSS), serum and CSF parameters
at onset and initial brain and/or spinal MRI images.
Location of spinal cord lesions was separated in two
groups; the first group included every lesion with cervi-
cal involvement (cervical (C1-C7), cervico-thoracic (C1-
Th12) or entire spinal cord (C1-conus)); the second
group included every lesion without cervical involve-
ment (thoracic (Th1-Th12) or thoraco-lumbar (Th1-
conus)). A longitudinally extensive lesion on spinal
MRI was defined as a lesion extending over three or
more contiguous segments. Consequently, a short lesion
on spinal MRI was defined as a lesion extending less
than three contiguous segments.
Patients and caregivers were instructed to contact the
hospital in case of new symptoms. A relapse was defined
as acute worsening of existing symptoms, or new symp-
toms after 30 days of improvement or stable disease, and
no evidence of alternative diagnosis. The symptoms
should exist for at least 24 hours and should not be pre-
ceded by fever. Relapses were confirmed by neurological
examination [10].
Final diagnosis at last follow-up was determined as
(1) monophasic idiopathic ATM, (2) ATM as first pre-
sentation of MS (defined by the IPMSSG) [8] (3)
ATM as first presentation of NMOSD (according to
current diagnostic criteria) [9] (4) ATM as a first presen-
tation of myelin oligodendrocyte glycoprotein (MOG)-
antibody-associated disorders (MOGAD) [11] or (5)
ATM as part of ADS with additional demyelinating fea-elapse and outcome in pediatric acute transverse myelitis. Brain Dev
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NMOSD or MOGAD criteria. Furthermore, disability
outcome was assessed at latest follow-up; poor outcome
was defined as EDSS score of  4 (restricted walking
distance or need for assistance to walk), while good out-
come was defined as EDSS score of < 4 (unrestricted
walking distance without aid).
2.3. Ethics approval / standard protocol approvals and
patient consents
The PROUD-kids study protocol was approved by
the Medical Ethical Committee of Erasmus MC Rotter-
dam and the other participating centers in the Nether-
lands. All patients and/or their families gave written
informed consent.
2.4. Systematic literature search
Previous published literature was systematically
searched in several databases including Embase, Med-
line Ovid, Cochrane, Web of Science and Google Scho-
lar until June 2020. The details of the search strategy are
provided in Appendix A. All results were reviewed by
two independent reviewers (JH and AB) and discrepan-
cies were discussed. Studies that reported prognostic fac-
tors for outcome of ATM in pediatric patients were
included if they met the following criteria: (1) compre-
hensible English language, (2) conducted after 1990
and (3) including  10 patients < 18 years old with
ATM. Patients with ATM due to underlying diseases
such as Behcet’s disease, Lyme borreliosis, or sarcoido-
sis were excluded. Moreover, if data regarding adult and
pediatric patients were not shown separately, studies
were excluded. Observational studies including random-
ized controlled studies (RCTs) or cohort studies were
eligible for inclusion. Letters, comments, conference
abstracts and reviews were excluded.
2.5. Statistical analysis
For descriptive and statistical analysis we used SPSS,
version 24.0 (SPSS Inc). Chi-square test and Fisher
Exact test were used for categorical data. Student’s t-
test and Mann-Whitney U test were used for continuous
data when appropriate. P-value < 0.05 was considered
significant. Correlation analyses between two continu-




In total, 69 children with transverse myelitis were
identified. Of these, four patients were excluded becausePlease cite this article in press as: Helfferich J et al. Prognostic factors for r
(2021), https://doi.org/10.1016/j.braindev.2020.12.019of a time to nadir longer than 21 days, and 16 patients
because of a final diagnosis of ADEM (Fig. 1). Forty-
nine cases of ATM were further analyzed for factors
associated with relapsing disease and poor outcome. In
these 49 children median age at onset was 13.1 years
(IQR 6.5–16.2, range 1.1–17.7), with a non-significant
overrepresentation of female patients (63%) (Table 1).
None of the patients had a medical condition that was
considered relevant for diagnosis of ATM. Virology
studies in CSF were performed in 34 patients (69%),
all with negative results. Virology studies in other spec-
imens were positive in five cases, showing enterovirus
(not further subtyped) in feces in one patient with a clin-
ical picture not consistent with acute flaccid myelitis. At
onset, three patients fulfilled the IPMSSG criteria for
MS and three patients fulfilled current Wingerchuk cri-
teria for NMOSD. Serum antibodies against MOG and
aquaporin-4 (AQP4) were found in respectively 7/31
(23%) and 2/35 (6%) patients. Median follow-up time
was 37 months (IQR 18–75 months), with a minimum
follow-up of 12 months.
3.2. Factors associated with relapsing disease
During follow-up, 35 patients remained monophasic.
The remaining 14 children had a relapsing disease and
were eventually diagnosed with MS (11/14, 79%),
NMOSD (2/14, 14%) or MOGAD (1/14, 7%). Compar-
ing patients with a relapsing and monophasic disease
course (Table 1), clinical factors at baseline that were
associated with relapsing disease were higher age (16.1
vs. 11.6 years, p = 0.002), longer time to nadir (5 vs.
3 days, p = 0.01) and lower maximum EDSS score at
the point of nadir (4.0 vs. 6.5, p = 0.003). In contrast,
presence of prodromal disease (57 vs. 14%, p = 0.007)
and radicular pain (57 vs. 7%, p = 0.001) were signifi-
cantly more often found in the monophasic group.
Almost all patients with relapsing disease showed
white matter lesions on initial cerebral MRI (13/14,
93%), compared to 44% of patients (14/35) with a
monophasic disease course (p = 0.002), fulfilling 2010
Revised McDonald criteria for dissemination in space
and time in 31% and 25% of these patients, respectively
(Table 1). All relapsing patients who fulfilled these crite-
ria were diagnosed with MS. On the other hand, in all
monophasic patients fulfilling these criteria, the white
matter lesions were atypical for MS (i.e. large, not well
circumscribed, involvement of basal ganglia and/or peri-
aqueductal gray) and none of these patients were diag-
nosed with MS. This demonstrates that these criteria
should only be applied in case of white matter lesions
suggestive of MS. Short lesions on initial spinal MRI
were significantly more often seen in the relapsing
patient group (64 vs. 21%, p = 0.006) and longitudinally
extensive lesions significantly more often in the
monophasic patient group (79 vs. 36%, p = 0.006).elapse and outcome in pediatric acute transverse myelitis. Brain Dev
Fig. 1. Description of the selection process, based on clinical TMCWG-criteria [4] and the subdivision in monophasic or relapsing disease and good
or poor outcome. ADEM: acute disseminated encephalomyelitis, ADS: acquired demyelinating syndrome, ATM: acute transverse myelitis,
MOGAD: myelin oligodendrocyte glycoprotein-antibody-associated disorders, MS: multiple sclerosis, NMOSD: neuromyelitis optica spectrum
disorders. * Including 1 AQP4-antibody positive patient.
4 J. Helfferich et al. / Brain & Development xxx (2021) xxx–xxxUnique oligoclonal bands in CSF were more often iden-
tified in relapsing disease (67 vs. 14%, p = 0.004). In our
cohort with only a small number of AQP4- (n = 2) and
MOG-antibody (n = 7) positive patients, presence of
these auto-antibodies was not associated with relapsing
disease. After exclusion of AQP4- and MOG-antibody
positive patients, all factors associated with relapsing
disease remained significant. Additionally, in this sub
analysis without antibody positive patients, elevated
CSF IgG (>0.55) was more often found in the relapsing
group (80 vs. 46%, p = 0.04).
At onset of disease, a total of 45 children (92%)
received treatment with intravenous methylprednisolone
(MPS). The remaining four did not receive any treat-
ment. None of the children with relapsing disease were
treated with intravenous immunoglobulins (IVIg) as
add-on treatment, compared to a third of monophasic
patients (p = 0.01). Follow-up time and eventual out-
come did not differ significantly between the relapsing
and monophasic group.
3.3. Factors associated with poor outcome
Nine out of 49 included pediatric ATM patients
(18%) had a poor outcome at final follow-up; five with
a monophasic disease (all ATM) and four with relapsing
disease (one AQP4-antibody seronegative NMOSD
patient and three MS patients). The NMOSD patient
died during follow-up due to respiratory failure based
on progressive brainstem involvement.
Patients with an MRI lesion without involvement of
the cervical spinal cord significantly more often had a
poor outcome (56 vs. 14%, p = 0.02), whereas patients
with an MRI lesion with involvement of the cervical
spinal cord more often had a good outcome (86 vs.
44%, p = 0.02) (Table 2). Headache occurred only in
patients with a good outcome (33 vs. 0%, p = 0.046).Please cite this article in press as: Helfferich J et al. Prognostic factors for r
(2021), https://doi.org/10.1016/j.braindev.2020.12.019Age at onset, sex, time to nadir, CSF leukocytosis, pres-
ence of serum antibodies, and duration of hospitaliza-
tion during first event were not associated with
outcome. Maximum EDSS score at onset did not differ
significantly between the good and poor outcome group.
However, a positive correlation between maximum
EDSS score at onset and EDSS score at last follow-up
was found (Spearman’s rho 0.36, p = 0.013). Relapses,
follow-up time and treatment type did not differ signifi-
cantly between the good and poor outcome group.
In our cohort with a limited number of AQP4- and
MOG-antibody positive patients, presence of autoanti-
bodies was not associated with poor outcome. Exclusion
of autoantibody positive patients did not change factors
significantly associated with poor outcome.
3.4. Systematic review
A total of 1029 articles were found with the described
search strategy (Appendix A). After screening based on
title and abstract, 48 articles were selected for full text
analysis. After reading the full text, 18 studies were
included and summarized in Table 3 [1,2,5,7,11–23].
Most studies were retrospective cohort studies with
less than 50 patients. The largest cohort was the study
described by Deiva et al. on prognostic factors for
relapsing disease and poor outcome in 95 children with
ATM [5]. There was a large heterogeneity in inclusion
criteria applied in included studies, with variation in
(1) definition of ATM, (2) in- or exclusion of transverse
myelitis associated with other diseases and (3) selected
age group, impairing comparison between included
studies.
A slight male preponderance was found in ten out of
16 cohorts (including the population based study by de
Goede et al., which described a male:female ratio of
1:0.64) [2]. However, analyzing the included patients inelapse and outcome in pediatric acute transverse myelitis. Brain Dev
Table 1
Clinical features and findings at onset of disease and at follow-up with a subdivision in monophasic and relapsing disease. For continuous values median and interquartile ranges (IQR) are shown.
*comparison between patients with a monophasic and relapsing disease course, **consistent with 2010 Revised McDonald criteria. AQP4: aquaporin-4, CSF: cerebrospinal fluid, DIS: dissemination
in space, DIT: dissemination in time, EDSS: Expanded Disability Status Scale, IgG: immunoglobulin G, IVIg: intravenous immunoglobulins, MOG: myelin oligodendrocyte glycoprotein, MPS:
methylprednisone, MRI: magnetic resonance imaging, n.a.: not applicable, nadir: maximum severity of clinical symptoms, NS: not significant, OCB: oligoclonal bands.
ONSET OF DISEASE All patients No. % Monophasic (35) % Relapsing (14) % P-value*
Demographics Age at onset (year) 13.1 (6.5–16.2) 49 n.a. 11.6 (5.2–15.7) n.a. 16.1 (13.6–17.0) n.a. 0.002
Male sex 18 49 37 14 40 4 29 NS
Clinical findings Prodromal disease 22 49 45 20 57 2 14 0.007
Time to nadir (days) 4.0 (3.0–5.5) 49 n.a. 3.0 (2.0–5.0) n.a. 5.5 (3.8–9.0) n.a. 0.01
Motor involvement 40 49 82 31 89 9 64 NS
Symmetry 14 40 35 12 39 2 22 NS
Sensory involvement 41 49 84 30 86 11 79 NS
Autonomic features 28 49 57 23 66 5 36 NS
Radicular pain 21 49 43 20 57 1 7 0.001
Optic neuritis 10 (3 bilateral) 49 20 8 23 2 14 NS
EDSS max 6.0 (4.0–7.5) 49 n.a. 6.5 (4.5–8.0) n.a. 4.0 (2.4–6.0) n.a. 0.003
Time in hospital 10 (5–17) 48 n.a. 11 (6–18) n.a. 5 (3–19) n.a. 0.048
MRI >3 vertebral segments 31 47 66 26 79 5 36 0.006
With cervical involvement 34 44 77 24 80 10 71 NS
Without cervical involvement 10 44 23 6 20 4 29 NS
Intracerebral white matter lesions 27 46 59 14 44 13 93 0.002
- Fulfilling DIS and DIT**  7  25  28  3  25  4  31 NS
CSF pleocytosis > 5 29 45 64 19 59 10 77 NS
protein > 0.5 15 45 34 13 42 2 15 NS
IgG > 0.55 24 39 62 14 52 10 83 NS
OCB 11 33 33 3 14 8 67 0.004
Antibodies MOG 7 31 23 6 25 1 14 NS
AQP4 2 35 6 1 4 1 13 NS
Treatment MPS 45 49 92 33 94 12 86 NS
IVIg 11 49 22 11 31 0 0 0.01
Plasmapheresis 4 49 8 4 11 0 0 NS
FOLLOW-UP
Recovery Follow-up time (months) 37 (18–75) 49 n.a. 31 (15–55) n.a. 61 (30–81) n.a. NS
EDSS 2.0 (1.0–3.0) 48 n.a. 1.5 (1.0–3.0) n.a. 2.5 (1.5–4.0) n.a NS






























































































Prognostic factors for poor outcome at onset of disease and follow-up. For continuous values median and interquartile ranges (IQR) are shown. P-
values are mentioned in the last column. AQP4: aquaporin-4, CSF: cerebrospinal fluid, EDSS: Expanded Disability Status Scale, IVIg: intravenous
immunoglobulins, MOG: myelin oligodendrocyte glycoprotein, MRI: magnetic resonance imaging, n.a.: not applicable, nadir: maximum severity of
clinical symptoms, NS: not significant.
ONSET OF DISEASE Good outcome (40) No. % Poor outcome (9) No. % P-value
Demographics Age at onset (year) 13.3 (7.6–16.1) 40 n.a. 12.2 (5.6–16.0) 9 n.a. NS
Male sex 16 40 40 2 9 22 NS
Clinical findings Time to nadir (days) 4.0 (3.0–5.0) 40 n.a. 3.0 (1.5–13.5) 9 n.a. NS
Headache 13 40 33 0 9 0 0.046
EDSS max 5.8 (4.0–7.5) 40 n.a. 7.0 (5.0–7.3) 9 n.a. NS
Time in hospital (days) 9 (5–17) 39 n.a. 14 (6–41) 9 n.a. NS
MRI with cervical involvement 30 35 86 4 9 44 0.02
without cervical involvement 5 35 14 5 9 56 0.02
CSF pleocytosis > 5 26 39 67 3 6 50 NS
Antibodies MOG 7 28 25 0 3 0 NS
AQP4 2 30 7 0 5 0 NS
Treatment IVIg 7 40 18 4 9 44 NS
FOLLOW-UP Follow-up time (months) 32 (17–61) 40 n.a. 64 (24–83) 9 n.a. NS
Relapses 10 40 25 4 9 44 NS
6 J. Helfferich et al. / Brain & Development xxx (2021) xxx–xxxthe reported cohorts all together, males and females
were almost equally divided (268 males vs. 259 females,
ratio 1:0.97). Most studies described a mean age, vary-
ing between 5.3 and 11.2 years. Only three studies men-
tioned the examination of AQP4 antibodies, which were
identified in five out of 48 examined patients (10%)
[5,18,20]. None of the included studies reported on the
presence of MOG antibodies.
Poor outcome was defined by the inability to walk
unassisted (EDSS  6) in most studies. Outcome was
variable among included studies, with poor outcome
reported in between 20 and 30% of patients. The occur-
rence of relapses was only reported in six studies, with
relapses occurring in 0–17% of patients during a
follow-up time ranging between 0.1 and 16.7 years.
Factors found to be associated with outcome and
relapsing disease course are mentioned in Table 3. A
shorter time to nadir and a greater severity of weakness
at nadir were mentioned in respectively five
[2,5,19,21,24] and six [1,5,7,18,19,24] different cohorts
as a prognostic factor for poor prognosis. Presence of
a short lesion on spinal MRI and abnormalities on brain
MRI were associated with relapsing disease and final
diagnosis of MS in several cohorts [5,15,18]. Early treat-
ment with high dose steroids and plasmapheresis may
improve outcome in pediatric ATM [14,17,23–25].
4. Discussion
In this study we confirmed known prognostic factors
and found new prognostic factors for relapse and poor
outcome in children with ATM. A longer time to nadir,
presence of a lesion shorter than three contiguous seg-
ments on spinal MRI, abnormalities on brain MRI
and presence of oligoclonal bands in CSF were predic-
tors for relapsing disease which were described before
[5,15,18,20]. In addition, our study found a higher agePlease cite this article in press as: Helfferich J et al. Prognostic factors for r
(2021), https://doi.org/10.1016/j.braindev.2020.12.019and a lower maximum EDSS score as new factors at
onset associated with following relapsing disease.
Not surprisingly, these factors are largely consistent
with features of MS and may point out that the profile
of ATM associated with MS is different than that of
monophasic ATM, as was previously suggested by
Meyer et al. [15] Also in adults, both a partial ATM,
as defined by less severe clinical deficits, and presence
of cerebral lesions on brain MRI are prognostic for
MS diagnosis [26,27].
The only factor associated with poor outcome in our
cohort was presence of a spinal cord lesion without cer-
vical involvement on MRI, while a lesion with involve-
ment of the cervical spinal cord was associated with
good outcome. This matches the finding by Deiva
et al., that absence of cervical (lesion within C1 to C7)
or cervico-thoracic (lesion within C1 to Th12) involve-
ment on spinal MRI was associated with poor outcome
[5]. This possibly represents a subgroup including MS
patients, since spinal cord lesions in MS are more often
found at the cervical level [28–30], and typically patients
with MS associated ATM show less residual symptoms
than other ATM patients [28].
The number of patients with a poor outcome in our
cohort was slightly lower than in most other cohorts
that described outcome in ATM in children
[2,5,16,18,21], especially the cohorts described by Deiva
et al. [5] and Pidcock et al. [16] An explanation could be
the higher age of our population compared to most
cohorts, since a younger age has been associated with
poor outcome in previous studies [12]. Furthermore,
older patients may be diagnosed earlier in the disease
course due to better recognition of their symptoms,
and thus may be treated sooner. Some studies have
shown that a delay in start of treatment was associated
with a worse outcome, although this could not be con-
firmed in our cohort [14,23].elapse and outcome in pediatric acute transverse myelitis. Brain Dev
Table 3
Systematic review. *2002 TMCWG criteria for ATM were used at least partially. #MRI of the brain was available in 27 of 39 patients. ADEM: acute disseminated encephalomyelitis, ATM: acute
transverse myelitis, CI: confidence interval, CSF: cerebrospinal fluid, FU: follow-up, LETM: longitudinally extensive transverse myelitis, MRI: magnetic resonance imaging, MPS:
































1. Shorter time to
nadir
2. Maximal severity of
weakness
3. Delay in onset of
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low risk of developing MS















1. Shorter time to
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2. Longer time to start
of treatment
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2. Early onset of
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3. Age under 10yrs
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1. Flaccid leg weakness
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involvement




































































































































































2. Absence of cervical
or cervico-thoracic
lesion
3. Time to nadir < 24 h





7. Pleocytosis > 10
1. Abnormal brain MRI
2. Time to nadir > 24 h
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Unknown 1. Lower age
2. Low reflexes
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1. Focal lesions associated
with MS diagnosis
2. LETM associated with
monophasic TM




























4. Greater mean time
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cervical spinal cord on
MRI
1. Higher age
2. Longer time to nadir
3. Lower maximal EDSS
4. MRI brain
abnormalities
5. MRI spine lesion < 3
segments





























































































10 J. Helfferich et al. / Brain & Development xxx (2021) xxx–xxxA shorter time to nadir, worse maximal deficits and a
delay in onset of recovery were mentioned to be predic-
tive for a poor outcome in several previous cohorts
(Table 3) [1,2,5,7,15,19,21,24]. In our study we could
not confirm these or other factors mentioned in Table 3,
although we did find a positive correlation between
maximum EDSS score at nadir and final follow-up.
An explanation may be found in the relatively low num-
ber of patients with a poor outcome in our cohort. Also,
the differences in demographics between our and other
cohorts could play a role, i.e. our study population con-
tained a higher proportion of females and the median
age was slightly higher compared to the other studies.
These differences may also be the reason for the rela-
tively high number of MS cases.
Previous studies on autoantibodies in pediatric ATM
are scarcely available, with MOG-antibody positivity in
22–43% and AQP4-antibody positivity in 7–10% in
small and selected cohorts [5,18,20,31,32]. Especially
AQP4-antibody positivity has been associated with a
relapsing disease course with a worse outcome as com-
pared to pediatric MS patients [33]. Of the MOG-
antibody positive pediatric patients, a small subgroup
will have relapses during follow-up, in particular those
with persisting MOG antibodies [11,34,35]. In our study,
presence of MOG or AQP4 antibodies was not a predic-
tor for relapsing disease or poor outcome. However, the
limited number of MOG- or AQP4-antibody positive
patients impairs proper investigation of this potentially
important subgroup of patients with ATM.
Our study has several strengths, which include a long
follow-up duration in most patients (median 37 months),
with a minimum follow-up of one year in all patients.
Furthermore, patients were assessed at least annually
during the entire follow-up period. Finally, our data
was collected as part of the PROUD-kids study, which
is a prospective study, in contrast to most previously
published retrospective cohorts.
A limitation of our study is the relatively small num-
ber of patients, precluding further statistical tests such
as logistic regression. As described earlier, differences
in demographic details hindered accurate comparison
of studies identified by our literature search. Neverthe-
less, many of the predictors for relapsing disease and
poor outcome did correspond with earlier studies. At
last, by using an EDSS score of 4 or higher as a mea-
surement for poor outcome, we focused on mobility
for defining a poor outcome, while for example pain
and bladder function may also influence quality of life
in children with ATM [6].
5. Conclusion
In this prospective cohort study we found different
factors associated with relapsing disease in pediatric
ATM, corresponding with typical MS features. InPlease cite this article in press as: Helfferich J et al. Prognostic factors for r
(2021), https://doi.org/10.1016/j.braindev.2020.12.019absence of these factors at onset of disease, pediatric
ATM patients are at low risk for relapses. Absence of
a cervical lesion on spinal cord MRI was prognostic
for a poor outcome in this study, while other features
such as a shorter time to nadir, a longer time to recovery
and severity of symptoms at nadir were found as predic-
tors for a poor outcome in literature.
Further research should focus on the use of AQP4-
and MOG-antibody serostatus and spinal MRI features,
such as involvement of gray matter, as prognostic mark-
ers in pediatric ATM.Acknowledgements
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